Matinas BioPharma's LNC Platform For The Delivery Of Small Oligonucleotides Featured In Two Presentations At The ASGCT Annual Meeting
Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of Matinas' LNC platform for the uptake and targeted delivery of small oligonucleotides.
Presentations:
| Title: | Lipid Nanocrystal Delivery of siRNA: Dynamics of Uptake in Innate Immune Cells in Human Blood and Visualization of Small Oligonucleotide Delivery in Cell Cultures |
| Format: | Oral Presentation |
| Location: | Room 314-317 |
| Date/Time: | May 10, 4:15 pm ET |
"In the first presentation we report on the dynamics of LNC uptake and cargo delivery ex vivo and in vitro and shows that LNCs – both with and without cargo – are avidly taken up by innate immune cells – like phagocytes – in human blood," said Dr. Ferguson. "We were also able to dynamically visualize the actual processes of LNC uptake and cargo delivery in cultured cells, with very different dynamics in somatic and cancer cells. These exciting data strongly support our belief that LNCs hold significant future promise for intracellular delivery of complex therapeutics."
| Title: | Successful In Vivo Oral Delivery of Biologically Active and Therapeutic Anti- Inflammatory mRNA-Targeted Oligonucleotides with a Lipid Nanocrystal Delivery Platform |
| Format: | Poster Session |
| Location: | Exhibit Hall |
| Date/Time: | May 10, 12:00-7:00 pm ET |
| Poster #: | 1709 |
"This second presentation builds on the in vitro work to show that our LNC platform can be used in vivo to orally deliver biologically active – and potentially therapeutic – oligonucleotides designed to target key cytokines in inflammatory disease models," added Dr. Ferguson. "We are currently focused on optimizing these LNC formulations to improve delivery efficiency, increase potency and extend application of oral cytokine-targeting oligo therapeutics to additional inflammatory disease models."